Cannabidiol and Older Adult Cannabis Users
Part of paid clinical trials in Boulder, Colorado.
- Sponsor
- University of Colorado, Boulder
- Study ID
- NCT06290063
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Anxiety
- Depression
- Pain
- Sleep
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- fsCBD Cannabidiol — DRUGFull Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
- bsCBD Cannabidiol — DRUGBroad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
- Placebo — DRUGPlacebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Study Details
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.
Key Dates
- Start date
- May 1, 2024
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 385 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Full-Spectrum Hemp-Derived CBD (fsCBD)8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)
- Experimental: Broad-Spectrum Hemp-Derived CBD (bsCBD)8 weeks of use of a daily dose of cannabis (200mg CBD)
- Placebo Comparator: Placebo
Primary Outcome Measure
Subjective Motor Function [ Time Frame: Baseline, 4 weeks, 8 weeks ]
Central Contacts
- Kyle A Chrystal, BA6037697718
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado at Boulder | Boulder | Colorado | 80309 | Ellie Sundali, BA |
Find similar trials in Boulder, CO
Related Studies
- RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for PainRecruiting · Boston Scientific Corporation · Phoenix, Arizona
- Anesthetics and Analgesics in ChildrenRecruiting · Chi Dang Hornik · Stanford, California
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 DiabetesRecruiting · Colorado State University · Aurora, Colorado